Wood R - Search Results

1

Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design.

Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Lawn SD, et al. Among authors: wood r. AIDS. 2005 Dec 2;19(18):2141-8. doi: 10.1097/01.aids.0000194802.89540.e1. AIDS. 2005. PMID: 16284464

2

Antiretroviral therapy in South Africa--can we do it?

Bekker LG, Wood R. Bekker LG, et al. Among authors: wood r. S Afr Med J. 2002 Mar;92(3):191-3. S Afr Med J. 2002. PMID: 12040936 Review. No abstract available.

3

Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.

Badri M, Wilson D, Wood R. Badri M, et al. Among authors: wood r. Lancet. 2002 Jun 15;359(9323):2059-64. doi: 10.1016/S0140-6736(02)08904-3. Lancet. 2002. PMID: 12086758

4

Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa.

Boulle A, Kenyon C, Skordis J, Wood R. Boulle A, et al. Among authors: wood r. S Afr Med J. 2002 Oct;92(10):811-7. S Afr Med J. 2002. PMID: 12432807

5

Adherence is not a barrier to successful antiretroviral therapy in South Africa.

Orrell C, Bangsberg DR, Badri M, Wood R. Orrell C, et al. Among authors: wood r. AIDS. 2003 Jun 13;17(9):1369-75. doi: 10.1097/00002030-200306130-00011. AIDS. 2003. PMID: 12799558 Clinical Trial.

6

Antiretroviral therapy in a community clinic--early lessons from a pilot project.

Bekker LG, Orrell C, Reader L, Matoti K, Cohen K, Martell R, Abdullah F, Wood R. Bekker LG, et al. Among authors: wood r. S Afr Med J. 2003 Jun;93(6):458-62. S Afr Med J. 2003. PMID: 12916388

7

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.

Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ. Wood R, et al. Antimicrob Agents Chemother. 2004 Jan;48(1):116-23. doi: 10.1128/AAC.48.1.116-123.2004. Antimicrob Agents Chemother. 2004. PMID: 14693528 Free PMC article. Clinical Trial.

8

Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines.

Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F, Wood R. Badri M, et al. Among authors: wood r. AIDS. 2004 May 21;18(8):1159-68. doi: 10.1097/00002030-200405210-00009. AIDS. 2004. PMID: 15166531

9

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

Gathe JC Jr, Ive P, Wood R, Schürmann D, Bellos NC, DeJesus E, Gladysz A, Garris C, Yeo J. Gathe JC Jr, et al. Among authors: wood r. AIDS. 2004 Jul 23;18(11):1529-37. doi: 10.1097/01.aids.0000131332.30548.92. AIDS. 2004. PMID: 15238771 Clinical Trial.

10

A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.

Wood R, Eron J, Arasteh K, Teofilo E, Trepo C, Livrozet JM, Yeo J, Millard J, Wire MB, Naderer OJ. Wood R, et al. Clin Infect Dis. 2004 Aug 15;39(4):591-4. doi: 10.1086/422452. Epub 2004 Jul 26. Clin Infect Dis. 2004. PMID: 15356829 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results